Trial Evaluates Innovative Imaging for Staging Cervical Cancer

October 11, 2007 — A new study conducted by the American College of Radiology Imaging Network (ACRIN) and the Gynecologic Oncology Group (GOG) is now underway to evaluate the ability of PET/CT with Fluorodeoxyglucose (FDG-PET/CT) and MRI with the contrast agent Combidex to identify pelvic and abdominal lymph node metastases in patients with locoregionally advanced cervical cancer.
According to study investigators, FDG-PET/CT and Combidex MRI offer promise for finding cancers that may presently go undiagnosed.
Approximately 10 ACRIN-approved sites will work in collaboration with a GOG member institution to accrue 325 participants within three years. All participants will undergo lymph node sampling to determine the accuracy of the imaging exams. Michael Gold, M.D., of the University of Oklahoma, is the GOG study chair.
For more information: www.acrin.org